Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Vordermark, Dirk ^a   Said, Harun M ^a   Katzer, Astrid ^a   Kuhnt, Thomas ^b   Hänsgen, Gabriele ^b   Dunst, Jürgen ^b,c   Flentje, Michael ^a   Bache, Matthias ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; UTERINE CERVIX CANCER;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; OSTEOPONTIN; SIALOGLYCOPROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 33748679942     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-207     Document Type: Article

References (24)

1. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003, 9:59-67.
2. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish Head and Neck Cancer Study Group: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6:757-764.
3. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, Haensgen G: Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003, 56:778-787.
4. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP: Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002, 20:680-687.
5. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005, 353:1564-1573.
6. Sorensen BS, Hao J, Overgaard J, Vorum H, Honore B, Alsner J, Horsman MR. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 2005, 76:187-193.
7. Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, Giaccia AJ, Le QT: Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 2005, 24:6555-6563.
8. Lukacova S, Khalil AA, Overgaard J, Alsner J, Horsman MR: Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum. Int J Radiat Biol 2006, 81:937-944.
9. Said HM, Katzer A, Flentje M, Vordermark D: Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. Radiother Oncol 2005, 76:200-205.
10. Rittling SR, Chambers AF: Role of osteopontin in tumor progression. Brit J Cancer 2004, 90:1877-1881.
11. Nordsmark M, Bentzen SM, Rudat V, Brizei D, Lartigau E, Stadier P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
12. Denhardt DT, Guo X: Osteopontin: a protein with diverse functions. FASEB J 1993, 7:1475-1482.
13. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T: Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000, 77:487-498.
14. Arai M, Yokosuka O, Kanda T, Fukai K, Imazeki F, Murumatsu M, Seki N, Miyazaki M, Ochiai T, Hirasawa H, Saisho H: Serum osteopontin levels in patients with acute liver dysfunction. Scand J Gastroenterol 2006, 41: 102-110.
15. Kadota J, Mizunoe S, Mito K, Mukae H, Yoshioka S, Kawakami K, Koguchi Y, Fukushima K, Kon S, Kohno S, Saito A, Uede T, Nasu M: High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir Med 2005, 99:111-117.
16. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F: Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003, 170:333-337.
17. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L: Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003, 53:819-822.
18. Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP, Elevation of plasma osteopontin level in patients with undifferendated nasopharyngeal carcinoma. Eur J Surg Oncol 2005, 31:555-558.
19. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC: Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005, 102:7677-7682.
20. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E, Imamura M: Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncol 2005, 68:285-92.
21. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287:1671-1679.
22. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC: Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004, 10:3474-3478.
23. Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella. T, Seiden MV: Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004, 93:361-365.
24. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han M, MA Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005, 11:4646-4652.